Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $460,000.

  • C4 Therapeutics' Depreciation & Amortization (CF) rose 4.07% to $460,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 13.74%. This contributed to the annual value of $1.8 million for FY2024, which is 3.30% down from last year.
  • Per C4 Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $460,000 for Q3 2025, which was down 25.20% from $615,000 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Depreciation & Amortization (CF) registered a high of $615,000 during Q2 2025, and its lowest value of $305,000 during Q1 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $456,000 (2025), whereas its average is $475,364.
  • In the last 5 years, C4 Therapeutics' Depreciation & Amortization (CF) crashed by 32.37% in 2022 and then surged by 78.69% in 2023.
  • Over the past 5 years, C4 Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $323,000 in 2021, then surged by 61.30% to $521,000 in 2022, then declined by 17.47% to $430,000 in 2023, then increased by 11.63% to $480,000 in 2024, then rose by 4.07% to $460,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $460,000 for Q3 2025, versus $615,000 for Q2 2025 and $456,000 for Q1 2025.